Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 11/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765926 | 0.92 | GAA (0.52) | GAAL3MBTL1TP53SMN1; SMN2ELANE | |
| SCHEMBL30765948 | 0.90 | LMNA (0.39) | GAACMA1ELANELMNACTSG | |
| SCHEMBL30765916 | 0.90 | CMA1 (0.41) | CMA1ELANELMNACTSGPOLB | |
| SCHEMBL31558452 | 0.89 | CMA1 (0.40) | CMA1ELANELMNACTSGCTRC | |
| SCHEMBL30766100 | 0.88 | GAA (0.42) | GAAL3MBTL1TP53SMN1; SMN2LMNA | |
| SCHEMBL30765921 | 0.86 | GAA (0.42) | GAAL3MBTL1TP53SMN1; SMN2ELANE | |
| SCHEMBL30766108 | 0.83 | GAA (0.39) | GAAL3MBTL1TP53SMN1; SMN2LMNA | |
| SCHEMBL30765884 | 0.83 | GAA (0.40) | GAAL3MBTL1TP53SMN1; SMN2LMNA | |
| SCHEMBL30765891 | 0.83 | GAA (0.40) | GAAL3MBTL1TP53SMN1; SMN2LMNA | |
| SCHEMBL30765983 | 0.81 | L3MBTL1 (0.38) | GAAL3MBTL1TP53SMN1; SMN2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |